<div><p>Noninvasive detection of both early pancreatic neoplasia and metastases could enhance strategies to improve patient survival in this disease that is notorious for an extremely poor prognosis. There are almost no identifiable targets for non-invasive diagnosis by positron emission tomography (PET) for patients with pancreatic ductal adenocarcinoma (PDAC). Over-expression of the receptor for advanced glycation end products (RAGE) is found on the cell surface of both pre-neoplastic lesions and invasive PDAC. Here, a RAGE-specific single chain (scFv) was developed, specific for PET imaging in syngeneic mouse models of PDAC. An anti-RAGE scFv conjugated with a sulfo-Cy5 fluorescence molecule showed high affinity and selectivity for RAGE ...
Purpose: Despite its widespread use, the PET radiotracer 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) ...
Pancreatic adenocarcinoma (PDAC) is one of the most lethal human cancers with a 5-year survival of l...
Rationale: The evaluation of early treatment response is critical for patient prognosis and treatmen...
Noninvasive detection of both early pancreatic neoplasia and metastases could enhance strategies to ...
Expression of the Receptor for Advanced Glycation End Products (RAGE) and is upregulated in a severa...
In this project we study the role of RAGE in the melanoma and pancreatic cancer progression. Based o...
Rationale: Despite its widespread use in oncology, the PET radiotracer 18F-FDG is ineffectivefor imp...
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy, as 90% of patients do not sur...
The Receptor for Advanced Glycation End Products (RAGE) has been shown to contribute to a myriad of ...
Purpose: Late-stage, unresectable pancreatic ductal adenocarcinoma (PDAC) is largely resistant to ch...
Background: Pancreatic cancer is among the most dismal of human malignancies. The 5-year survival ra...
Background: Pancreatic cancer is among the most dismal of human malignancies. The 5-year survival ra...
ABSTRACTPancreatic ductal adenocarcinoma (PDAC) is a devastating disease with low survival rates. Cu...
Pancreatic stellate cells (PSCs) mainly consist of cancer-associating fibroblasts in pancreatic duct...
Oncogenic KRAS is central to several cancer types including pancreatic ductal adenocarcinoma (PDAC),...
Purpose: Despite its widespread use, the PET radiotracer 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) ...
Pancreatic adenocarcinoma (PDAC) is one of the most lethal human cancers with a 5-year survival of l...
Rationale: The evaluation of early treatment response is critical for patient prognosis and treatmen...
Noninvasive detection of both early pancreatic neoplasia and metastases could enhance strategies to ...
Expression of the Receptor for Advanced Glycation End Products (RAGE) and is upregulated in a severa...
In this project we study the role of RAGE in the melanoma and pancreatic cancer progression. Based o...
Rationale: Despite its widespread use in oncology, the PET radiotracer 18F-FDG is ineffectivefor imp...
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy, as 90% of patients do not sur...
The Receptor for Advanced Glycation End Products (RAGE) has been shown to contribute to a myriad of ...
Purpose: Late-stage, unresectable pancreatic ductal adenocarcinoma (PDAC) is largely resistant to ch...
Background: Pancreatic cancer is among the most dismal of human malignancies. The 5-year survival ra...
Background: Pancreatic cancer is among the most dismal of human malignancies. The 5-year survival ra...
ABSTRACTPancreatic ductal adenocarcinoma (PDAC) is a devastating disease with low survival rates. Cu...
Pancreatic stellate cells (PSCs) mainly consist of cancer-associating fibroblasts in pancreatic duct...
Oncogenic KRAS is central to several cancer types including pancreatic ductal adenocarcinoma (PDAC),...
Purpose: Despite its widespread use, the PET radiotracer 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) ...
Pancreatic adenocarcinoma (PDAC) is one of the most lethal human cancers with a 5-year survival of l...
Rationale: The evaluation of early treatment response is critical for patient prognosis and treatmen...